Nelarabine

Structural formula
General
Surname	Nelarabine
other names	9-β- D -arabinofuranosyl-6-methoxyguanine; 9 - [(2 R , 3 S , 4 S , 5 R ) -3,4-dihydroxy-5- (hydroxymethyl) oxolan-2-yl] -2-amino-6-methoxy-purine;
Molecular formula	C 11 H 15 N 5 O 5
External identifiers / databases
EC number	642-916-9
ECHA InfoCard	100.170.768
PubChem	3011155
ChemSpider	2280207
DrugBank	DB01280
Wikidata	Q1216264
Drug information
ATC code	L01 BB07
Drug class	Cytostatic
properties
Molar mass	297.27 g mol −1
Physical state	firmly
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Nelarabine is a rare nucleoside . It consists of a furanose (sugar) and 6- O -methylguanine . It contains - in contrast to most nucleosides - instead of β- D -Ribofuranose the β- D -Arabinofuranose and thus belongs to the group of arabinosyl nucleosides . The corresponding nucleoside with ribose is 6- O -methylguanosine . Nelarabine is used as a cytostatic drug .

literature

M. Sanford, KA Lyseng-Williamson: "Nelarabine", Drugs , 2008 , 68 (4), pp. 439-447 ( PMID 18318562 ).
MH Cohen, JR Johnson, R. Justice, R. Pazdur: "FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia / lymphoma", Oncologist , 2008 , 13 (6), p. 709– 714 ( doi : 10.1634 / theoncologist.2006-0017 , PMID 18586926 ).

Entry for nelarabine in the Human Metabolome Database (HMDB) , accessed October 12, 2013.

↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.